逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
  • About Us
    • Company Profile
    • Business Model
    • Board of Directors
    • Management Team
    • Scientific Advisory Board
    • Others
  • R & D
    • Pipeline Overview
    • SIF Pipeline
      • FP-001:Prostate Cancer; Central Precocious Puberty
      • FP-014:Prostate Cancer
      • FP-016:Neurology/Psychiatry
      • FP-004:Opioid Dependence/Pain
      • FP-011:Breast Cancer
      • Other Research Projects
    • NCE Pipeline
      • FP-025:Asthma; Acute Exacerbations of COPD/ILD
      • FP-045: Fanconi Anemia; Cardiovascular, Renal and Metabolism (CVRM); Peripheral artery disease (PAD)
      • FP-020: Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
      • FP-040: CNS Diseases
  • Media
    • Press Release
    • Media Library
  • Investors
    • Corporate Governance
      • Corporate Charters
      • Board of Directors
      • Others
    • Material Information
    • News & Events
      • Press Releases
      • Events & Presentations
    • Financial Information
      • Financial Results
      • Monthly Revenues
    • Sharholder Information
      • Annual General Meeting
      • Major Shareholders
      • FAQs
      • Investor Contacts
    • Others
  • Career
    • Benefits
    • Join Us
  • Contact Us
  • 繁體中文
  • HOME
  • 繁體中文
  • HOME

Media

Press Release

Keyword Search
  • Date
    Title
  • 2022-05-31
    Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
  • 2022-04-04
    Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
  • 2022-02-23
    Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
  • 2021-05-26
    Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
  • 2021-03-28
    Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
  • 2021-03-04
    Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
  • 2020-12-24
    Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
  • 2020-11-17
    Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China
  • 2020-10-09
    Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA
  • 2020-09-17
    Foresee Pharmaceuticals to Present at the 2020 Fanconi Anemia Scientific Symposium
Total 23 ( 10 records per page )    Next  Go page
  • Press Release
  • Media Library

Foresee Pharmaceuticals Co., Ltd.

Copyright © 2020 Foresee Pharmaceuticals Co., Ltd. All rights reserved.